Watch Ticker

BiomX Inc.

Go to BiomX Inc. Website

$0.58

0.15 (34.46%)

Live

Previous Close

$0.435

Day Range

$0.4945 - $0.7212

Previous Day Range

$0.4 - $0.45

Market Cap

$11.4 million USD

Day Vol.

193.0 million

Previous Day Vol.

20.3 million

Currency

USD

Primary Exchange

NYSE American, LLC

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers an...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Jonathan Solomon - BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

BiomX initiated a Phase 2b clinical trial for BX004, a phage therapy targeting Pseudomonas aeruginosa infections in cystic fibrosis patients. The trial involves 60 patients and aims to evaluate bacterial reduction, lung function improvements, and quality of life metrics, with topline results expected in Q1 2026.

Related tickers: PHGE.

Read Full Article

N/A - BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

BiomX, a clinical-stage company, announced that it will host a conference call to report its first quarter 2025 financial results and provide business updates.

Related tickers: PHGE.

Read Full Article

Trending Tickers

Please sign in to view